What is the current price and volume for GV.PA stock today?

GV.PA stock trades around **€0.002** intraday on 18 Feb 2026 with volume near **38,489,238** shares, about **2.71x** the average daily volume. This activity makes the name one of the most active on EURONEXT today.

What is Meyka AI's rating and forecast for GV.PA stock?

Meyka AI rates GV.PA with a score out of 100 at **62.42** (Grade **B**, Suggestion: **HOLD**). Meyka AI's forecast model projects a 12-month midpoint target of **€0.00500**, implying **+177.78%**, with standard caveats that model projections are not guarantees.

What are the main risks for investors in GV.PA stock?

Principal risks include micro-cap liquidity, negative EPS (**-€0.11**), weak current ratio (**0.91**), possible shareholder dilution and cash-flow strain. These factors increase volatility and the chance of sharp downside moves.

Are there catalysts that could raise GV.PA stock price?

Catalysts include new commercial deals for FiberVision, validation studies, larger partnerships or successful product adoption in diagnostics. Broader demand for genomic testing, as noted in recent industry trial news, could support interest in GV.PA.

EU Stocks

GV.PA Genomic Vision SA (EURONEXT) €0.002 on 18 Feb 2026: heavy intraday volume

ByDanny Kontos February 18, 2026February 18, 2026

Genomic Vision SA (GV.PA) is trading at €0.002 intraday on 18 Feb 2026, up 5.88% as volume surges to 38,489,238 shares. This volume is roughly 2.71x the 50-day average and places GV.PA stock among the most active names on EURONEXT today. Traders are responding to micro-cap volatility and sector news that may lift demand for genomic testing tools.